4-BROMO-3-HYDROXY-5-(3-(4-METHOXYPHENYL)-1-PHENYL-1H-PYRAZOL-4-YL)FURAN-2(5H)-ONE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ABGOQIOEUGAQMS-UHFFFAOYSA-N
Smiles	COc1ccc(cc1)c2nn(cc2C3OC(=O)C(=C3Br)O)c4ccccc4
InChI	InChI=1S/C20H15BrN2O4/c1-26-14-9-7-12(8-10-14)17-15(19-16(21)18(24)20(25)27-19)11-23(22-17)13-5-3-2-4-6-13/h2-11,19,24H,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H15BrN2O4
Molecular Weight	427.25
AlogP	4.07
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	73.58
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	27.0

Assay Description	Organism	Bioactivity
Inhibition of GSK3alpha/beta (unknown origin)	Homo sapiens	10000.0 nM
Inhibition of CDK5/p25 (unknown origin)	Homo sapiens	10000.0 nM
Inhibition of Marthasterias glacialis CDK1/cyclin B using histone H1 as substrate and [gamma32P]ATP after 10 min by scintillation counting	Marthasterias glacialis	10000.0 nM
Antifungal activity against Candida albicans ATCC 10231 at 1 mg/ml after 24 hr by agar cup diffusion method	Candida albicans	15.0 mm

Cross References

Resources	Reference
ChEMBL	CHEMBL2262588
PubChem	76323080

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).